Holen Sie sich die Stockscreener-App
1.67
2.34%
-0.04
Handel nachbörslich:
1.69
0.02
+1.20%
Schlusskurs vom Vortag:
$1.71
Offen:
$1.71
24-Stunden-Volumen:
138.58K
Relative Volume:
0.35
Marktkapitalisierung:
$50.61M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-25.94M
KGV:
-1.2101
EPS:
-1.38
Netto-Cashflow:
$-15.79M
1W Leistung:
-2.34%
1M Leistung:
-10.70%
6M Leistung:
-13.02%
1J Leistung:
-55.47%
1-Tages-Spanne:
$1.66
$1.72
1-Wochen-Bereich:
$1.64
$1.90
52-Wochen-Spanne:
$1.40
$4.24
MAIA Biotechnology Inc Stock (MAIA) Company Profile
Firmenname
MAIA Biotechnology Inc
Sektor
Branche
Telefon
312 416 8592
Adresse
444 West Lake Street, Suite 1700, Chicago
Vergleichen Sie MAIA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MAIA
MAIA Biotechnology Inc
|
1.67 | 52.62M | 0 | -25.94M | -15.79M | -1.38 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
MAIA Biotechnology Inc Aktie (MAIA) Neueste Nachrichten
Is MAIA Biotechnology Inc. a good long term investmentBreakthrough financial growth - jammulinksnews.com
What analysts say about MAIA Biotechnology Inc. stockGame-changing capital returns - jammulinksnews.com
MAIA Biotechnology Inc. Stock Analysis and ForecastExplosive capital gains - jammulinksnews.com
MAIA Biotechnology’s 41% decline validates InvestingPro’s overvalued call By Investing.com - Investing.com
What drives MAIA Biotechnology Inc. stock priceExceptional earning trajectories - Autocar Professional
Is MAIA Biotechnology Inc. stock a growth or value playMomentum Swing Watchlist - beatles.ru
When is the best time to buy MAIA Biotechnology Inc. stockPro Trader Stock Focus - Newser
Maia Biotechnology stock soars after publishing promising preclinical data - Investing.com
MAIA Biotechnology Publishes Promising Preclinical Cancer Data - TipRanks
MAIA Biotechnology publishes preclinical data on cancer drug candidates By Investing.com - Investing.com Canada
Maia Biotechnology stock soars after publishing promising preclinical data By Investing.com - Investing.com Canada
MAIA Biotechnology publishes preclinical data on cancer drug candidates - Investing.com
MAIA Biotechnology Announces Peer-Reviewed Journal Publication of Data Validating Second Generation Ateganosine Prodrugs for Anticancer Therapy - Business Wire
Why MAIA Biotechnology Inc. stock attracts strong analyst attentionFree Stock Selection - Newser
How MAIA Biotechnology Inc. stock performs during market volatilityFree Stock Investment Discussion Area - Newser
What makes MAIA Biotechnology Inc. stock price move sharplySteady Profit Stock Forecasts - Newser
MAIA Biotechnology doses first patient in expansion of Phase II lung cancer trial - Yahoo Finance
MAIA Biotechnology doses first patient in Taiwan for NSCLC trial By Investing.com - Investing.com South Africa
MAIA Biotechnology Announces First Patient Dosed in Expansion of Phase 2 Trial for Ateganosine in Advanced Non-Small Cell Lung Cancer - BioSpace
MAIA Biotechnology Begins Phase 2 Trial Expansion - TipRanks
MAIA Biotechnology (NYSEAMERICAN:MAIA) Trading Up 0.5% – Still a Buy? - Defense World
Public market insider buying at Canaccord Genuity Group (CF) - The Globe and Mail
MAIA Biotechnology to Present Two Posters Featuring Cancer Telomere-Targeting Agents at FEBS 2025 Congress - BioSpace
Maia Biotechnology enters stock purchase agreement for up to $587,905 with Prevail Partners - Investing.com
MAIA Biotechnology, Roche Partner for Hard-to-Treat Cancer Therapies - Contract Pharma
MAIA Biotechnology appoints HCC experts to scientific advisory board - Investing.com
MAIA Biotechnology, Roche sign supply agreement for cancer therapies - Yahoo Finance
MAIA Biotechnology partners with Roche for cancer treatment studies By Investing.com - Investing.com South Africa
Maia Biotechnology Signs Clinical Supply Deal With Roche; Shares Rise - MarketScreener
MAIA Biotech (MAIA) Partners with Roche for Cancer Treatment Study - GuruFocus
MAIA Biotechnology, Inc. Announces Master Clinical Supply Agreement with Roche for Hard-To-Treat Cancer Therapies - marketscreener.com
Finanzdaten der MAIA Biotechnology Inc-Aktie (MAIA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
Kapitalisierung:
|
Volumen (24h):